IBRX
ImmunityBio Inc

19,373
Mkt Cap
$2.11B
Volume
11.57M
52W High
$5.43
52W Low
$1.83
PE Ratio
-5.09
IBRX Fundamentals
Price
$2.02
Prev Close
$2.14
Open
$2.19
50D MA
$2.42
Beta
2.07
Avg. Volume
9.46M
EPS (Annual)
-$0.6189
P/B
-4.02
Rev/Employee
$21,683.82
Loading...
Loading...
News
all
press releases
A Fresh $16 Million Bet on ImmunityBio: What Investors Should Know
Key PointsBought 6,565,709 shares of ImmunityBio, an increase of $16.15 million in position value...
Nasdaq News: Markets·1d ago
News Placeholder
More News
News Placeholder
ImmunityBio (NASDAQ:IBRX) Receives "Buy" Rating from D. Boral Capital
D. Boral Capital restated a "buy" rating and set a $24.00 target price on shares of ImmunityBio in a research report on Thursday...
MarketBeat·6d ago
News Placeholder
New Survey Reveals Non-Muscle Invasive Bladder Cancer Patients Seek More Care Conversations
A new U.S. survey conducted by The Harris Poll on behalf of ImmunityBio, Inc. (NASDAQ: IBRX) reveals that many people living with non-muscle invasive bladder cancer (NMIBC) feel left out of critical...
Business Wire·7d ago
News Placeholder
Analysts Set Expectations for ImmunityBio FY2025 Earnings
ImmunityBio, Inc. (NASDAQ:IBRX - Free Report) - Equities research analysts at HC Wainwright increased their FY2025 earnings estimates for shares of ImmunityBio in a report released on Wednesday...
MarketBeat·11d ago
News Placeholder
HC Wainwright Increases Earnings Estimates for ImmunityBio
ImmunityBio, Inc. (NASDAQ:IBRX - Free Report) - Investment analysts at HC Wainwright lifted their FY2029 earnings per share (EPS) estimates for shares of ImmunityBio in a research report issued to...
MarketBeat·12d ago
News Placeholder
ImmunityBio (NASDAQ:IBRX) Earns "Buy" Rating from D. Boral Capital
D. Boral Capital reissued a "buy" rating and set a $24.00 price objective on shares of ImmunityBio in a research note on Wednesday...
MarketBeat·14d ago
News Placeholder
Driven by Strong Demand, ImmunityBio Reports 467% Year-to-Date Unit Growth and $75 Million in Sales Year-to-Date, Up 434% from Q3 2024
ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced its financial results for the fiscal quarter and nine months ended September 30, 2025. In the third quarter of 2025...
Business Wire·16d ago
News Placeholder
Myriad Genetics (MYGN) Reports Break-Even Earnings for Q3
Myriad (MYGN) delivered earnings and revenue surprises of +100.00% and +0.24%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·17d ago
News Placeholder
ImmunityBio Stock Breaks Out Of Long Slump, Tests $3 Zone: Ex-UBS Analyst Flags ‘Huge’ Bullish Signals
The stock’s recent momentum has been fueled by fresh optimism around trial data for its cancer drug Anktiva, which showed survival benefits in resistant lung cancer patients.
Stocktwits·2mo ago
News Placeholder
Not Just Opendoor & GoPro: JPMorgan Identifies 4 Emerging 'Meme Stocks' Firing Up Social Media And Hedge Fund Shorts
Meme mania has resurged in the past few months.
Stocktwits·2mo ago

Latest IBRX News

View

Advertisement|Remove ads.

Advertisement|Remove ads.